ArticleBlood2013

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.

Jing Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.